AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Devonian Health Group Inc.
Video analysis: DVHGF
All videosNo video analysis for this stock yet. Request one from our team.
News: DVHGF
Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
QUEBEC, Sept. 11, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offering, it anticipates to list its common shares and warrants offered on the NYSE American LLC with trading expected to commence as early as September 16, 2026 under the symbols "DHGR" and "DHGR WS", respectively, subject to market conditions and final authorization by the NYSE American LLC of the Company's listing application and continued compliance with the exchange rules.
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
Validated HPLC-MS, NMR and a validated cell-based biological potency assay using the U937 human cell line, with MIP-1β as a biological marker of Thykamine™'s anti-inflammatory activity, provide complementary chemical and biological measures of Thykamine™ and demonstrate reliable batch-to-batch consistency. QUEBEC, Sept.
Devonian Health Group Anticipates to Commence Trading on the NYSE American
QUEBEC, Aug. 18, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offering, it anticipates to list its common shares and warrants offered on the NYSE American LLC with trading expected to commence as early as August 21, 2026 under the symbols "DHGR" and "DHGR WS", respectively, subject to market conditions and final authorization by the NYSE American LLC of the Company's listing application and continued compliance with the exchange rules. The Company will remain listed on the TSX Venture Exchange (the "TSXV").
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering PR Newswire
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the NYSE American LLC (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of the Company's listing application and continued compliance with the exchange rules.
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. Secondary objectives include assessment of the overall safety and tolerability.
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 PR Newswire
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
(all amounts are in Canadian dollars) Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share Cash as of April 30, 2026, $0.7 million Company remains debt-free QUÉBEC, June 29, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and nine months ended April 30, 2026. ''We are pleased with the continued momentum to execute on our priorities and readiness to advance our pipeline'', said Dr. André P.
Similar companies
-
Hemostemix Inc
HMTXF
·
Other OTC
Compare
-
Algorae Pharmaceuticals Limited
LVCLF
·
Other OTC
Compare
-
Nymox Pharmaceutical Corporation
NYMXF
·
Other OTC
Compare
-
Oxford BioDynamics Plc
OXBOF
·
Other OTC
Compare
-
Inhibitor Therapeutics, Inc.
INTI
·
Other OTC
Compare
-
SpotLite360 IOT Solutions, Inc.
SPLTF
·
Other OTC
Compare